9M 2023 Financial Performance

9M 2023: APPENDIX Rexulti 1,500 1,200 900 600 300 38 Rexulti revenue (Quarterly DKKm) 4,000 +12% reported 3,000 2,000 1,000 Rexulti revenue (9M - DKKm) REXULTI +17% reported 0 0 Q3.20 Q3.21 Q3.22 Q3.23 9M 2020 9M 2021 9M 2022 9M 2023 United States Other regions Unless otherwise stated, growth rates are at CER. Rexulti was approved by the FDA July 2015 and by the EU Commission July 2018 Comments • • Grew 19% (+17% reported) to DKK 3.3bn in 9M 2023 Strong demand growth continues in the U.S. and other regions Rexulti franchise protected for several years: . • Composition of matter patent expires in June 2029 (including extensions) Patents issued lasting to November 2032

View entire presentation